US Exchange Filings

BioCardia Reports Nasdaq Equity Shortfall, Plans to Seek Compliance Extension

BioCardia shares remain trading on Nasdaq, but the company’s stockholders’ equity has fallen below the exchange’s minimum, putting its continued listing in question. Investors will be watching as BioCardia prepares a plan to address the shortfall by January 4, 2027.

BioCardia has fallen below Nasdaq’s minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Its common stock remains listed and trading under the symbol BCDA for now, while the company seeks time to address the shortfall.

  • BioCardia reported stockholders’ equity of $835,000 as of September 30, 2026, below Nasdaq’s $2.5 million minimum.
  • The company has until January 4, 2027, to submit a plan to regain compliance. BioCardia says it intends to do so.
  • If Nasdaq accepts the plan, it may give the company up to 180 calendar days from November 20, 2026, to demonstrate compliance.
  • Nasdaq will assess the plan’s prospects and BioCardia’s financial condition, among other factors. If Nasdaq rejects the plan, BioCardia may request a hearing before a Nasdaq panel.
  • The notice does not immediately affect the listing or trading of BioCardia shares. The stock continues to trade on the Nasdaq Capital Market as BCDA.

The immediate issue is a minimum-equity shortfall, not a suspension of trading. Continued listing will depend on Nasdaq’s review of BioCardia’s plan and whether the company can meet the exchange’s requirements within any period granted.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.